Abstract
The ongoing COVID-19 pandemic accompanied by the emergence of new successive pathogenic variants makes problematic the prospects of the approach based on application of exclusively prophylactic vaccines to combat SARSCoV-2. This reason motivated the urgent need in search and development of chemical formulas showing direct antiviral action.The present mini-review provides data on chemical and enzymatic methods of producing molnupiravir regarded so far as one of the most effective pharmaceuticals for treatment of COVID-19. In conclusion of the literature survey it is suggested to administer lipid-containing analog instead of molnupiravir in COVID-19 therapeutic protocols. In this respect the authors reported the successful synthesis catalyzed by bacterial phospholipase D of 5′-dimyristoyl derivative of N4-hydroxycytidine – the compound allegedly more efficient than molnupiravir in inhibiting SARS-CoV-2 replication.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Proceedings of the National Academy of Sciences of Belarus, Biological Series
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
